At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMLX Amylyx Pharmaceuticals
Trading 12-08 14:15:55 EST
13.91
-0.29
-2.04%
High14.76Low13.84Vol566.15K
Open14.29D1 Closing14.20Amplitude6.44%
Mkt Cap1.53BTradable Cap910.40MTotal Shares109.82M
T/O7.99MT/O Rate0.87%Tradable Shares65.45M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies
Reuters  ·  12-06
BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies
BUZZ-Amylyx rises after promising early-stage trial for ALS drug
Reuters  ·  12-05
BUZZ-Amylyx rises after promising early-stage trial for ALS drug
BRIEF-Amylyx Pharmaceuticals Announces New Safety And Tolerability Cohort 1 Data Of Amx0114
Reuters  ·  12-05
BRIEF-Amylyx Pharmaceuticals Announces New Safety And Tolerability Cohort 1 Data Of Amx0114
Amylyx Reports Positive Early Safety Data for AMX0114 in ALS Phase 1 LUMINA Trial
Reuters  ·  12-05
Amylyx Reports Positive Early Safety Data for AMX0114 in ALS Phase 1 LUMINA Trial
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of Amx0114 in ALS From First-in-Human Lumina Trial
THOMSON REUTERS  ·  12-05
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of Amx0114 in ALS From First-in-Human Lumina Trial
Amylyx Pharmaceuticals Inc - Amx0114 Well-Tolerated With No Serious Adverse Events
THOMSON REUTERS  ·  12-05
Amylyx Pharmaceuticals Inc - Amx0114 Well-Tolerated With No Serious Adverse Events
Amylyx Pharmaceuticals Chief Medical Officer Camille L. Bedrosian Reports Disposal of Common Shares
Reuters  ·  12-04
Amylyx Pharmaceuticals Chief Medical Officer Camille L. Bedrosian Reports Disposal of Common Shares
Amylyx Pharmaceuticals Q3 EPS USD -0.37 Vs. IBES Estimate USD -0.47
Reuters  ·  11-20
Amylyx Pharmaceuticals Q3 EPS USD -0.37 Vs. IBES Estimate USD -0.47
Is Amylyx (AMLX) Reshaping Its Investment Case With Improved Losses and Avexitide’s Path to Market?
Simply Wall St.  ·  11-14
Is Amylyx (AMLX) Reshaping Its Investment Case With Improved Losses and Avexitide’s Path to Market?
Stock Track | Amylyx Pharmaceuticals Soars Nearly 7% as Mizuho Boosts Price Target
Stock Track  ·  11-10
Stock Track | Amylyx Pharmaceuticals Soars Nearly 7% as Mizuho Boosts Price Target
Stock Track | Amylyx Pharmaceuticals Soars 5.61% Pre-Market as Mizuho Raises Target Price
Stock Track  ·  11-10
Stock Track | Amylyx Pharmaceuticals Soars 5.61% Pre-Market as Mizuho Raises Target Price
Stock Track | Amylyx Pharmaceuticals Surges 5.61% Pre-Market on Mizuho's Target Price Hike
Stock Track  ·  11-10
Stock Track | Amylyx Pharmaceuticals Surges 5.61% Pre-Market on Mizuho's Target Price Hike
Assessing Amylyx Pharmaceuticals (AMLX) Valuation Following Recent Share Price Momentum
Simply Wall St.  ·  11-09
Assessing Amylyx Pharmaceuticals (AMLX) Valuation Following Recent Share Price Momentum
Amylyx Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  11-08
Amylyx Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Amylyx Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $20 From $16
THOMSON REUTERS  ·  11-07
Amylyx Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $20 From $16
Should Amylyx Pharmaceuticals' Sharply Reduced Net Losses Prompt a Rethink by AMLX Investors?
Simply Wall St.  ·  11-07
Should Amylyx Pharmaceuticals' Sharply Reduced Net Losses Prompt a Rethink by AMLX Investors?
Amylyx Pharma Q3 loss narrows
Reuters  ·  11-06
Amylyx Pharma Q3 loss narrows
Amylyx Pharmaceuticals Reports Third Quarter 2025 Results and Extends Cash Runway Into 2028
Reuters  ·  11-06
Amylyx Pharmaceuticals Reports Third Quarter 2025 Results and Extends Cash Runway Into 2028
BRIEF-Amylyx Pharmaceuticals Q3 EPS USD -0.37 Vs. IBES Estimate USD -0.47
Reuters  ·  11-06
BRIEF-Amylyx Pharmaceuticals Q3 EPS USD -0.37 Vs. IBES Estimate USD -0.47
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  11-06
Calendar of U.S. Earnings Expected in the Week Ahead

Introduction

Company Name.
Amylyx Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Issue price:
--